Chimerix (CMRX) said Monday it has submitted a new drug application with the US Food and Drug Administration for the accelerated approval of its experimental drug, dordaviprone, which is intended to treat a type of tumor caused by a mutation in the histone 3 gene.
The company said it has requested a priority review, which could lead to a decision by Q3 2025.
Chimerix also said it has entered an amended loan agreement with Silicon Valley Bank for up to $30 million.
The agreement allows the company to draw up to $20 million through February 2026, with an additional $10 million available upon approval through February 2027.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。